Protein kinase C inhibitors: a patent review (2010 – present)

Bibliography

• Newton AC, Protein Kinase C. Structure, function, and regulation. J Biol Chem 1995;270:28495-8
   PubMed Web of Science ®Google Scholar
• Saito N, Shirai Y. Protein kinase C gamma (PKC gamma): function of neuron specific isotype. J Biochem 2002;132:683-7
   PubMed Web of Science ®Google Scholar
• Reyland ME. Protein kinase C delta and apoptosis. Biochem Soc Trans 2007;35:1001-4
   PubMed Web of Science ®Google Scholar
• Susan FS. Structural basis of protein kinase C isoform function. Physiol Rev 2008;88:1341-78
   Google Scholar
• Newton AC. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr Biol 1995;5:1394-403
   Google Scholar
• Bharath A, Robert VS, Michelle AD, et al. Activation mechanisms of conventional protein kinase C isoforms are determined by the ligand affinity and conformational flexibility of their C1 domains. J Biol Chem 2003;278:46886-94
   Google Scholar
• Koya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats (pkcβ activation). J Clin Invest 1997;100:115-26
   PubMed Web of Science ®Google Scholar
• Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001;44:659-73
   PubMed Web of Science ®Google Scholar
• Pass JM, Zheng Y, Wead WB, et al. PKCepsilon activation induces dichotomous cardiac phenotypes and modulates PKCepsilon-RACK interactions and RACK expression. Am J Physiol Heart Circ Physiol 2001;280:946-55
   Google Scholar
• Meier M, Menne J, Haller H. Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice. Diabetologia 2009;52:765-75
   PubMed Web of Science ®Google Scholar
• Yang XM, Sato H, Downey JM, et al. Protection of ischemic preconditioning is dependent upon a critical timing sequence of protein kinase C activation. J Mol Cell Cardiol 1997;29:991-9
   Google Scholar
• Wang Y, Takashi E, Xu M, et al. Downregulation of protein kinase C inhibits activation of mitochondrial K (ATP) channels by diazoxide. Circulation 2001;104:85-90
   PubMed Web of Science ®Google Scholar
• Fryer RM, Wang Y, Hsu AK, et al. Essential activation of PKC-delta in opioid-initiated cardioprotection. Am J Physiol Heart Circ Physiol 2001;280:1346-53
   PubMed Web of Science ®Google Scholar
• Bonizzi G, Piette J, Schoonbroodt S, et al. Role of the protein kinase C lambda/iota isoform in nuclear factor-kappaB activation by interleukin-1beta or tumor necrosis factor-alpha: cell type specificities. Biochem Pharmacol 1999;57:713-20
   PubMed Web of Science ®Google Scholar
• Qiming JW, Ganwei L, Walter AS, et al. The V5 domain of protein kinase C plays a critical role in determining the isoform-specific localization, translocation, and biological function of protein kinase C-δ and –ε. Mol Cancer Res 2004;2:129-40
   Google Scholar
• Soderling TR. Protein Kinases: regulation by autoinhibitory domains. J Biol Chem 1990;265:1823-6
   PubMedGoogle Scholar
• Newton AC. Protein kinase C seeing two domains. Curr Biol 1995;9:973-6
   Google Scholar
• Yesim GP, Alan P. Mapping of a molecular determinant for protein kinase C βII Isozyme function. J Biol Chem 1998;273:20261-6
   Google Scholar
• Qiming JW, Ganwei Lu, Walter AS, et al. The V5 domain of protein kinase C plays a critical role in determining the isoform-specific localization, translocation, and biological function of protein kinase C -δ and -ε. Mol Cancer Res 2004;2:129-40
   Google Scholar
• CompleGen, Inc. Compounds and methods for PKC theta inhibition. US20100120869A1; 2010
   Google Scholar
• Janssen Pharmaceutica, NV. Beerse (BE), Substituted pyrroline as kinase inhibitors. US7759380B2; 2010
   Google Scholar
• Janssen Pharmaceutica, NV. Beerse (BE), Substituted pyrrolines as kinase inhibitors. US7786135B2; 2010
   Google Scholar
• Janssen Pharmaceutica, NV. Beerse (BE), Substituted pyrroline as kinase inhibitors. US7781450B2; 2010
   Google Scholar
• Janssen Pharmaceutica, NV. Beerse (BE), Substituted pyrroline as kinase inhibitors. US7705015B2; 2010
   Google Scholar
• Janssen Pharmaceutica, NV. Beerse (BE), Indazolyl-substituted pyrroline compound as kinase inhibitors. US7855203B2; 2010
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors. US8012966B2; 2011
   Google Scholar
• Albert Einstein College of Medicine of Yeshiva University. Protein kinase inhibitors and methods for identifying same. US7902330B2; 2011
   Google Scholar
• Das EN, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007;55:498-510
   PubMed Web of Science ®Google Scholar
• Churchill E, Budas G, Vallcntin A, et al. PKC Isozymes in Chronic Cardiac Disease: possible Therapeutic Targets? Annu Rev Pharmacol 2008;48:569-99
   Google Scholar
• Meier M, King GL. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med 2000;5:173-85
   PubMed Web of Science ®Google Scholar
• Whiteside CI, Dlugosz JA. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol Renal Physiol 2002;282:975-80
   PubMed Web of Science ®Google Scholar
• Dlugosz JA, Munk S, Ispanovic E, et al. Mesangial cell filamentous actin disassembly and hypocontractility in high glucose are mediated by PKC-zeta. Am J Physiol Renal Physiol 2002;282:151-63
   Google Scholar
• Lindschau C, Quass P, Menne J, et al. Glucose-induced TGF-{beta} 1 and TGF-{beta} receptor-1 expression in vascular smooth muscle cells is mediated by protein Kinase C-{alpha}. Hypertension 2003;42:335-41
   Google Scholar
• Silva GB, Garvin JL. Angiotensin II-dependent hypertension increases Na transport-related oxygen consumption by the thick ascending limb. Hypertension 2008;52:1091-8
   Google Scholar
• Itani SI, Zhou Q, Pories WJ, et al. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 2000;49:1353-8
   PubMed Web of Science ®Google Scholar
• Tony KT, Hidenori Y, Andrew HC, et al. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-δ. Am J Physiol Endocrinol Metab 2002;283:E682-91
   Google Scholar
• Yu Li, Timothy JS, Xinghai Li, et al. Protein kinase C θ inhibits insulin signaling by PHOSPHORYLATING IRS1 at Ser1101. J Biol Chem 2004;279:45304-7
   Google Scholar
• He Z, King GL. Protein kinase C isoform inhibitors a new treatment for diabetic cardiovascular diseases. Circulation 2004;110:7-9
   Google Scholar
• Koya D, King GL, Protein Kinase C. Activation and the development of diabetic complications. Diabetes 1998;47:859-66
   PubMed Web of Science ®Google Scholar
• Avignon A, Sultan A. PKC-β inhibition: a new therapeutic approach for diabetic complications? Diabetes Metab 2006;32:205-13
   PubMed Web of Science ®Google Scholar
• Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527-37
   PubMed Web of Science ®Google Scholar
• Idris I, Donnelly R. Protein kinase C β inhibition: a novel therapeutic strategy for diabetic microangiopathy. DiabVasc Dis Res 2006;3:172-8
   Google Scholar
• Malhotra A, Begley R, Kang BPS, et al. PKC-ε-dependent survival signals in diabetic hearts. AJP - Heart 2005;289:H1343-50
   Google Scholar
• Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002;133:693-8
   PubMed Web of Science ®Google Scholar
• Menne J, Shushakova N, Hermann H, et al. Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy. Diabetes 2013;62:1167-74
   PubMed Web of Science ®Google Scholar
• Bonke VT, Cooper ME. Tandem inhibition of PKC in diabetic nephropathy it takes two to tango? Diabetes 2013;62:1010-11
   Google Scholar
• Teicher BA. Protein kinase C as therapeutic target. Clin Cancer Res 2006;12:5336-45
   PubMed Web of Science ®Google Scholar
• Cornford P, Evans J, Dodson A, et al. Protein Kinase C. Isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 1999;154:137-44
   PubMed Web of Science ®Google Scholar
• French AD, Fiori JL, Camilli TC, et al. PKC and PKA Phosphorylation affect the subcellular localization of claudin-1 in melanoma cells. Int J Med Sci 2009;6:93-101
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng C, Knight ZA, et al. EGFR Signals to mTOR through PKC and independently of Akt in glioma. Sci Signal 2009;2:1-19
   Google Scholar
• Yazaki T, Ahmad S, Chahlavi A, et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioateoligodeoxynucleotide. Mol Pharmacol 1996;50:236-42
   PubMed Web of Science ®Google Scholar
• Hu JG, Wang XF, Zhou JS, et al. Activation of PKC-alpha is required for migration of C6 glioma cells. Acta Neurobiol Exp (Wars) 2010;70:239-45
   Google Scholar
• University of South Florida. Use of pkc-iota inhibitors for the treatment of breast cancer. WO 20121037553A2; 2012
   Google Scholar
• Vertex Pharmaceuticals Inc. Kinase inhibitors. US8173635B2; 2012
   Google Scholar
• Pharmacopeia, LLC. Purinones and 1H-imidazopyridinones as PKC-theta inhibitors. US7989459B2; 2011
   Google Scholar
• Sledge GW, Gokmen PY. Protein kinase C-beta as a therapeutic target in breast cancer. SeminOncol 2006;33:15-18
   Google Scholar
• Martiny BG, Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res 2007;55:477-86
   Google Scholar
• Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer's disease. Cold Spring HarbPerspect Med 2012;2:1-24
   Google Scholar
• Etcheberrigaray R, Tan M, Dewachter I, et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. PNAS 2004;101:11141-6
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Novel 3-amino-pyrrolo [3,4-c]pyrazole-5(1 h,4 h,6 h) carbaldehyde derivatives. US20100130501A1; 2010
   Google Scholar
• Yiwei S, Chen W, Song H, et al. Determination of PKC isoform-specific protein expression in pulmonary arteries of rats with chronic hypoxia-induced pulmonary hypertension. Med Sci Monit 2012;18:69-75
   Google Scholar
• Von Hahn T, Schulze A, Chicano Wust I, et al. The novel immunosuppressive protein kinase c inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus. PLoS One 2011;6:1-9
   Google Scholar
• Fuller TF, Kusch A, Chaykovska L, et al. Protein kinase C inhibition ameliorates posttransplantation preservation injury in rat renal transplants. Transplantation 2012;94:679-86
   Google Scholar
• Ohara Y, Sayegh HS, Yamin JJ, et al. Regulation of endothelial constitutive nitric oxide synthase by protein kinase C. Hypertension 1995;25:415-20
   PubMed Web of Science ®Google Scholar
• Novartis AG. Substituted pyrrole-2, 5-diones as protein kinase C inhibitors. US7851475B2; 2010
   Google Scholar
• Diane HB. Small molecule inhibitors of PKCθ as potential anti-inflammatory therapeutics. Curr Top Med Chem 2009;9:640-54
   Google Scholar
• Wyeth LLC, Madison NJ. Indole-substituted 3-cyanopyridines as kinase inhibitors. US20110028455 A1; 2011
   Google Scholar
• Novartis AG. Cyclic ether compounds useful as kinase inhibitors. WO2012004217A1; 2012
   Google Scholar
• Novartis AG. Basel (CH), Indolylmaleimide derivatives as PKC inhibitors. US7648989B2; 2010
   Google Scholar
• Do JS, Park KS, Seo HJ, et al. Therapeutic target validation of protein kinase C (PKC)-zeta for asthma using a mouse model. Int J Mol Med 2009;23:561-6
   Google Scholar
• Nechushtan H, Leitges M, Cohen C, et al. Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase C β. Blood 2000;95:1752-7
   PubMedGoogle Scholar
• He Z, Madsen CR, King GL. Managing heart disease Mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies. Eur Heart J 2003;5:B51-7
   Google Scholar
• Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase Cβ-deficient mice. Science 1996;273:788-91
   PubMed Web of Science ®Google Scholar
• Fisher GJ, Talwar HS, Baldassare JJ, et al. Increased Phospholipase C-Catalyzed Hydrolysis of Phosphatidylinositol-4, 5-Bisphosphate and 1,2-sn-Diacylglycerol Content in Psoriatic Involved Compared to Uninvolved and Normal Epidermis. J Invest Dermatol 1990;95:428-35`
   PubMed Web of Science ®Google Scholar
• Harrington EO, Nelson PR, et al. Enhancement of migration by protein kinase Cα and inhibition of proliferation and cell cycle progression by protein kinase Cδ in capillary endothelial cells. J Biol Chem 1997;272:7390-7
   PubMed Web of Science ®Google Scholar
• Raynaud F, Brion DE. Protein kinase C activity in normal and psoriatic cells: cultures of fibroblasts and lymphocytes. Brit J Dermatol 1991;124:542-6
   Google Scholar
• N.V. Organon, Pharmacopeia, LLC. Purines as pkc-theta inhibitors. US20110046131A1; 2011
   Google Scholar
• Novartis AG. Basel (CH), Indolylmaleimide derivatives as PKC inhibitors. US7648989B2; 2010
   Google Scholar
• Novartis AG. Substituted pyrrole-2, 5-diones as protein kinase C inhibitors. US7851475B2; 2010
   Google Scholar
• The Board of Trustees of the Leland Stanford Junior University. Peptide inhibitors of PKC. US7833984B2; 2010
   Google Scholar
• The Board of Trustees of the Leland Stanford Junior University. Peptides derived from the C2 domain of epsilon PKC. US7851587B2; 2010
   Google Scholar
• Pfizer, Inc. Novel 3-amino-pyrrolo [3,4-c]pyrazole-5(1 h,4 h,6 h) carbaldehyde derivatives. US20100130501A1; 2010
   Google Scholar
• N.V. ORGANON. Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors. US20110218189A1; 2011
   Google Scholar
• Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors. US8013153B2; 2011
   Google Scholar
• Board of Trustees of the Leland Stanford Junior University. Peptide inhibitors of protein kinase C. US7939493B2; 2011
   Google Scholar
• IRM LLC, a Delware Ltd. Corp. Compounds and compositions as protein kinase inhibitors. US8101608B2; 2012
   Google Scholar
• Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof. WO20121012619 A1; 2012
   Google Scholar
• Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof. US20120022092 A1; 2012
   Google Scholar
• Pharmagap Inc. Inhibitors of protein kinases and uses thereof. US8158586B2; 2012
   Google Scholar
• Vertex Pharmaceuticals Inc. Pyrazolopyridine kinase inhibitors. US201210071494 A1; 2012
   Google Scholar
• Vertex Pharmaceuticals Inc. Tri-cyclic pyrazolopyridine kinase inhibitors. US20120136000 A1; 2012
   Google Scholar
• Novartis Ag. Crystalline forms of pkc alpha kinase, methods of making such crystals, and uses thereof. WO 2008037688 A2; 2008
   Google Scholar
• Novartis Ag. Three-dimensional structure of the catalytic domain of protein c theta, methods and use thereof. WO 2004076654 A1; 2004
   Google Scholar